靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2003-12-31 |
A Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions
This is a Phase 1, Randomized, Open-Label, Three-Treatment, Three-Period Crossover Study to Assess Bioequivalence and Safety of TTYP01 Tablets to Radicava® Injection, and Radicava ORS® in Healthy Adult Subjects Under Fasting Conditions.The objective is To characterize the bioequivalence、safety and tolerability of TTYP01 tablets and Radicava® injection or Radicava ORS®in healthy adult subjects under fasted conditions.In this study, 30 healthy adult subjects will receive TTYP01, or Radicava, orRadicava ORS in each period according to the randomization sequence.
100 项与 Auzone Biological Technology Pty Ltd 相关的临床结果
0 项与 Auzone Biological Technology Pty Ltd 相关的专利(医药)
100 项与 Auzone Biological Technology Pty Ltd 相关的药物交易
100 项与 Auzone Biological Technology Pty Ltd 相关的转化医学